 |
|
||||||
|
|||||||
HepaLife™ to Present Bioartificial Liver Device Data at International Stem Cell ConferenceBoston, MA – April 16, 2008 – HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that the Company will present new data from ongoing research and development of its artificial liver device technology at the 6th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 11-14, 2008. The conference will be held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The world’s premier stem cell research event, the ISSCR Annual Meeting attracts an elite audience of researchers, biotechnology visionaries and governmental representatives to discuss and present findings at the forefront of stem cell research. Entitled “Maintenance of hepatic cell function by the PICM-19H Porcine Liver Stem Cell Line cultured in a bioartificial liver”, the data will be presented by Neil C. Talbot, PhD, USDA Agricultural Research Service, Animal Biosciences and Biotechnology Laboratory. “We are honored to present at the ISSCR Conference,” stated Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc. “This leading stem cell research meeting is an important forum to discuss HepaLife’s research accomplishments. Our research team has made significant progress on the development of our bioartificial liver device, including our patented PICM-19 liver stem cell line. We very much look forward to sharing new data from our bioartificial liver program with the scientific community.” Earlier this month HepaLife announced that the Company’s proprietary bioartificial liver device has successfully demonstrated key liver functions in a model of the human liver failure environment, prompting researchers to move towards in vivo animal studies. Please see press release from April
7, 2008 In tests designed to represent the environment present when treating human liver failure patients, HepaLife’s patented PICM-19 liver cells were exposed to human blood plasma and toxic ammonia. Notably, HepaLife’s PICM-19 cell line successfully removed toxic ammonia, produced urea, and expressed CYP-450 enzymes - - all leading indicators of liver function. HepaLife is presenting additional artificial liver data and research findings at the 54th Annual Meeting of the American Society of Artificial Internal Organs (ASAIO) in San Francisco, June 19-21, 2008. Please see press release from March 25, 2008
Intended for the treatment of liver failure, the HepaLife™ Bioartificial Liver device consists of three basic components: (1) a plasma filter, separating the patient’s blood into blood plasma and blood cells; (2) the bioreactor, a unit filled with the patented PICM-19 liver stem cell line which biologically mimics the liver’s function; and (3), the HepaDrive™, a perfusion system for pumping the patient's plasma through the bioreactor while controlling gas supply and temperature for best possible performance of the cells. Positive results from recent in-vitro tests of HepaLife's proprietary bioartificial liver were announced earlier this month. The ammonia utilization models constructed from data collected during successive PICM-19 cell hollow-fiber bioreactor runs indicate that the Bioartificial Liver device currently exhibits an excess of the capacity needed to treat animals in initial in-vivo tests. The same in-vitro experiments have confirmed that the capacity for ammonia removal and urea production by the PICM-19 cell line is unaffected by the presence of normal human serum - an important milestone leading towards initial in-vivo trials. International Society for Stem Cell Research (ISSCR)
Based in Boston, Massachusetts, HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based medical technologies addressing prevalent human health concerns. Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses. For additional information, please visit www.hepalife.com. To receive future press releases via email, please visit: To view the full HTML text of this release, please visit:
# # # #
Legal Notice Regarding Forward-Looking Statements No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company makes no commitment to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
© Copyright 2009 HepaLife Technologies, Inc. All Rights Reserved.